Image source: Juno Therapeutics.
Within the first four weeks of 2016, Juno Therapeutics (NASDAQ: JUNO) had shed over 40% of its market value. Since then, though, shares of the biotech have staged a nice comeback. While Juno’s stock is still down around 13% year to date, the situation looks much better now than it did in early February.